Pass-Through Status Will Continue Under the New Code Through June 30, 2023 MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 8, 2021-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that the
MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 17, 2020-- Presentation time in the release dated December 17, 2020 , should read 2 p.m. ET (instead of 5 p.m. ET ). The updated release reads: INTERSECT ENT TO PRESENT AT THE 39 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Intersect ENT, Inc.
MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 11, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced Neil Hattangadi , M.D., M.Sc . joined the Intersect ENT Board of Directors. Dr.
Study Initiates with Registration on ClinicalTrials.gov MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 29, 2021-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it began the process of
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the U.S. Food and Drug Administration ( FDA ) has performed a Pre-Approval Inspection
MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 28, 2021-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital
MENLO PARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Intersect ENT (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the Company has been added to the Russell 2000 ® index, effective as of the close of
MENLO PARK, Calif. --(BUSINESS WIRE)--May 11, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it has closed a $65 million convertible notes financing with a fund managed by Deerfield Management
